Top

11-03-2017 | Vasculitis | Article

Birmingham Behçet’s service: classification of disease and application of the 2014 International Criteria for Behçet’s Disease (ICBD) to a UK cohort

Journal: BMC Musculoskeletal Disorders

Authors: Tim Blake, Luke Pickup, David Carruthers, Erika Marie Damato, Alastair Denniston, John Hamburger, Claire Maxton, Debbie Mitton, Philip I. Murray, Peter Nightingale, Ana Poveda-Gallego, Andrea Richards, Andrew Whallett, Deva Situnayake

Publisher: BioMed Central

Abstract

Background

This study reports on the analysis of the application and diagnostic predictability of the revised 2014 ICBD criteria in an unselected cohort of UK patients, and the ensuing organ associations and patterns of disease.

Methods

A retrospective cohort study was conducted using a database of electronic medical records. Three categories were recognised: clinically defined BD, incomplete BD and rejected diagnoses of BD. We applied the ISG 1990 and ICBD 2014 classification criteria to these subgroups to validate diagnostic accuracy against the multidisciplinary assessment.

Results

Between 2012 and 2015, 281 patients underwent initial assessment at an urban tertiary care centre: 190 patients with a confirmed diagnosis of BD, 7 with an incomplete diagnosis, and 84 with a rejected diagnosis. ICBD 2014 demonstrated an estimated sensitivity of 97.89% (95% CI: 94.70 to 99.42) and positive likelihood ratio of 1.21 (1.10 to 1.28). The strongest independent predictors were: Central nervous lesions (OR = 10.57, 95% CI: 1.34 to 83.30); Genital ulceration (OR = 9.05, 95% CI: 3.35 to 24.47); Erythema nodosum (OR = 6.59, 95% CI: 2.35 to 18.51); Retinal vasculitis (OR = 6.25, 95% CI: 1.47 to 26.60); Anterior uveitis (OR = 6.16, 95% CI: 2.37 to 16.02); Posterior uveitis (OR = 4.82, 95% CI: 1.25 to 18.59).

Conclusions

The ICBD 2014 criteria were more sensitive at picking up cases than ISG 1990 using the multidisciplinary assessment as the gold standard. ICBD may over-diagnose BD in a UK population. Patients who have an incomplete form of BD represent a distinct group that should not be given an early diagnostic label. Behçet’s disease is a complex disease that is best diagnosed by multidisciplinary clinical assessment. Patients in the UK differ in their clinical presentation and genetic susceptibility from the original descriptions. This study also highlights an incomplete group of Behçet’s patients that are less well defined by their clinical presentation.

Morton LT, Situnayake D, Wallace GR. Genetics of Behcet’s disease. Curr Opin Rheumatol. 2016;28:39–44.CrossRefPubMed

Feigenbaum A. Description of Behçet’s syndrome in the Hippocratic third book of endemic diseases. Br J Opthalmol. 1956;40:355.CrossRef

Behçet H. Uber rezidivierende, aphthose durch ein virus verursachte geschwure am mund, am auge und an der genitalen. Dermatol Wochenschr. 1937;1152.

Mutlu S, Scully C. The person behind the eponym: Hulûsi Behçet (1889–1948). J Oral Pathol Med. 1994;23:289.CrossRefPubMed

Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:148–55.CrossRefPubMed

Yurdakul S, Hamuryudan V, Yazici H. Behcet’s Syndrome. Curr Opin Rheumatol. 2004;16:38.CrossRefPubMed

Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behcet’s disease in the US: a population-based study. Arthritis Rheum-Arthritis Care Res. 2009;61:600–4.CrossRef

Dundar SV. Familial clusters of Behcet’s disease. Behcets Dis: Basic Clin Asp. 1991;8:49–51.

Akpolat T, Koç Y, Yeniay I, Akpek G, GüllüI I, Kansu E, Kiraz S, Ersoy F, Batman F, Kansu T. Familial Behçet’s disease. Eur J Med. 1992;1:391–5.PubMed

10.

International Study group for Behçet’s disease. Criteria for the diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.

11.

O’Neill T, Rigby A, Silman A, Barnes C. Validation of the International Study Group criteria for Behcet’s disease. Br J Rheumatol. 1994;33:115–7.CrossRefPubMed

12.

Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, et al. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRef

13.

Whallett AJ, Thurairajan G, Hamburger J, Palmer RG, Murray PI. Behcet’s syndrome: a multidisciplinary approach to clinical care. QJM-Mon J Assoc Physicians. 1999;92:727–40.CrossRef

14.

Torres R, Yáñez B, Herreras J, Calonge M. Ocular Behçet disease. Retrospective study. Arch Soc Esp Oftamol. 2004;79:599–603.

15.

Okada A, Stanford M, Tabbara K. Ancillary testing, diagnostic/classification criteria and severity grading in Behçet disease. Ocul Immunol Inflamm. 2012;20:387–93.CrossRefPubMed

16.

June RR, Aggarwal R. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014;28:921–34.CrossRefPubMed

17.

Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet’s disease. Arch Ophthalmol. 1982;100:1455–8.CrossRefPubMed

18.

de Menthon M, LaValley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Care Res. 2009;61:1287–96.CrossRef

19.

Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54:213–20.CrossRefPubMed

20.

Arida A, Vaiopoulos G, Markomichelakis N, Kaklamanis P, Sfikakis PP. Are clusters of patients with distinct clinical expression present in Behcet’s disease? Clin Exp Rheumatol. 2009;27:S48–51.PubMed

21.

Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, et al. Mapping the HLA association in Behcet’s disease - A role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807–13.CrossRefPubMed

22.

Bennani N, Atouf O, Benseffaj N, Brick C, Essakalli M. HLA polymorphism and Behcet’s disease in Moroccan population. Pathol Biol. 2009;57:403–9.CrossRefPubMed

23.

Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behcet’s disease: a comprehensive review. J Autoimmun. 2015;64:137–48.CrossRefPubMedPubMedCentral

24.

Kamiishi T, Itoh Y, Meguro A, Nishida T, Sasaki S, Nanba K, Ohno S, Inoko H, Mizuki N. Four-digit allele genotyping of HLA-A and HLA-B genes in Japanese patients with Behcet’s disease (BD) by a PCR-SSOP-Luminex method and stratification analysis according to each major symptom of BD. Nippon Ganka Gakkai Zasshi. 2008;112:451–8.PubMed

25.

Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, Yamakawa R, Yuasa T, Fujioka T, Ohno S, et al. Genetics of Behcet disease inside and outside the MHC. Ann Rheum Dis. 2010;69:747–54.CrossRefPubMed

26.

Yazici H, Chamberlain MA, Tuzun Y, Yurdakul S, Muftuoglu A. A comparative study of the pathergy reaction among Turkish and British patients with Behçet’s disease. Ann Rheum Dis. 1984;43:74–5.CrossRefPubMedPubMedCentral

27.

Bonitsis NG, Nguyen LBL, LaValley MP, Papoutsis N, Altenburg A, Koetter I, Micheli C, Maldini C, Mahr A, Zouboulis CC. Gender-specific differences in Adamantiades-Behçet’s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology. 2015;54:121–33.CrossRefPubMed